France launches biotech fund

Experts say new fund not sufficient to address chronic biotech funding shortage

Written byJane Burgermeister
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The French government has launched a new investment fund to attract capital to the country's languishing medium-sized biotech companies. However, scientists argue that the fund is not nearly generous enough to help ease the chronic investment shortage for French biotech companies hoping to grow into global players.

The fund -- termed the fund of funds for technology (le Fonds de Fonds Technologique (FFT)) - plans to spend 150 million euros each year over the next three years, matching VC investments in medium-sized companies that have the potential to go to the stock market. In contrast to previous funds, which have distributed funding more equally among companies, the FFT will support VCs targeting companies that have been identified as innovative and most likely to bring new products to the market according to the highly competitive criteria of the European Investment Bank, which is itself contributing 50 million euro to the FFT.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies